699 reports of this reaction
1.7% of all CALCITRIOL CAPSULES 0.25 MCG reports
#17 most reported adverse reaction
END STAGE RENAL DISEASE is the #17 most commonly reported adverse reaction for CALCITRIOL CAPSULES 0.25 MCG, manufactured by Strides Pharma Science Limited. There are 699 FDA adverse event reports linking CALCITRIOL CAPSULES 0.25 MCG to END STAGE RENAL DISEASE. This represents approximately 1.7% of all 42,159 adverse event reports for this drug.
Patients taking CALCITRIOL CAPSULES 0.25 MCG who experience end stage renal disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
END STAGE RENAL DISEASE is a less commonly reported adverse event for CALCITRIOL CAPSULES 0.25 MCG, but still significant enough to appear in the safety profile.
In addition to end stage renal disease, the following adverse reactions have been reported for CALCITRIOL CAPSULES 0.25 MCG:
The following drugs have also been linked to end stage renal disease in FDA adverse event reports:
END STAGE RENAL DISEASE has been reported as an adverse event in 699 FDA reports for CALCITRIOL CAPSULES 0.25 MCG. This does not prove causation, but indicates an association observed in post-market surveillance data.
END STAGE RENAL DISEASE accounts for approximately 1.7% of all adverse event reports for CALCITRIOL CAPSULES 0.25 MCG, making it a notable side effect.
If you experience end stage renal disease while taking CALCITRIOL CAPSULES 0.25 MCG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.